Eculizumab: A guide to its use in atypical haemolytic uraemic syndrome

Drugs and Therapy Perspectives

Volumn 30, Issue 5, 2014, Pages 166-172

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; ECULIZUMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLOOD TRANSFUSION; CHRONIC KIDNEY DISEASE; DISEASE DURATION; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; EVENT FREE SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION;

EID: 84899762902     PISSN: 11720360     EISSN: 11791977     Source Type: Journal    
DOI: 10.1007/s40267-014-0120-x     Document Type: Article

References (29)

1. Westra D, Wetzels JF, Volokhina EB, et al. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome. Neth J Med. 2012;70(3):121-9.
2. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
3. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-81.
4. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment: a consensus document. Nefrologia. 2013;33(1):27-45.
5. Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26(1):41-57.
6. Hodgkins KS, Bobrowski AE, Lane JC, et al. Clinical grand rounds: atypical hemolytic uremic syndrome. Am J Nephrol. 2012;35(5):394-400.
7. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-87.
8. Langman C. Systemic multi-organ complications in atypical hemolytic uremic syndrome (aHUS): retrospective study in a medical practice setting [abstract no. 0490]. Haematologica. 2012;97(Suppl 1):195-6.
9. Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643-57.
10. Schmidtko J, Peine S, El-Housseini Y, et al. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61(2):289-99.
11. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematol Am Soc Hematol Educ Program. 2012;2012:617-25.
12. Fakhouri F, Fremeaux-Bacchi V, Loirat C. Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy. Eur J Intern Med. 2013;24(6):492-5.
13. Soliris (eculizumab): EU summary of product characteristics. London: European Medicines Agency; 2014.
14. Soliris® (eculizumab): US prescribing information. Cheshire (CT): Alexion Pharmaceuticals, Inc.; 2012.
15. Alexion Pharmaceuticals, Inc. Researchers to present new data on Soliris® (eculizumab) as a treatment for patients with aHUS at ASN Annual Meeting [media release]. 2013. http://news.alexionpharma.com. Accessed 10 Feb 2014.
16. Keating GM. Eculizumab: a review of its use in atypical haemololytic uraemic syndrome. Drugs. 2013;73(18):2053-66.
17. Fakhouri F, Hourmant M, Campistol JM, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult atypical hemolytic uremic syndrome (aHUS) patients (pts) [abstract]. In: Kidney Week 2013; 5-10 Nov 2013; Atlanta (GA).
18. Greenbaum LA, Fila M, Tsimaratos M, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric atypical hemolytic uremic syndrome (aHUS) patients (pts) [abstract]. In: Kidney Week 2013; 5-10 Nov 2013; Atlanta (GA).
19. Lapeyraque A-L, Simonetti G, Vilalta R, et al. Efficacy and safety of eculizumab treatment for atypical hemolytic uremic syndrome (aHUS) in pediatric patients: outcomes from a retrospective study [abstract no. 095]. In: Canadian Society of Nephrology Annual Meeting; 25-30 Apr 2012; St. John's (NL).
20. Vilalta R, Al-Akash SI, Davin J, et al. Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: efficacy and safety outcomes of a retrospective study [abstract no. 1155]. Haematologica. 2012;97(Suppl 1):479.
21. Greenbaum L, Legendre CM, Babu S, et al. Eculizumab (ECU) in atypical hemolytic uremic syndrome (aHUS) patients with progressing thrombotic microangiopathy (TMA): 2-year data [abstract no. 2084]. Blood. 2012;120.
22. Licht C, Muus P, Legendre CM. Eculizumab (ECU) safety and efficacy in atypical hemolytic uremic syndrome (aHUS) patients with long disease duration and chronic kidney disease (CKD): 2-year results [abstract no. 985]. Blood. 2012;(120).
23. Licht C, Muus P, Legendre CM, et al. Eculizumab in aHUS patients with a long disease duration and chronic kidney disease: 2-year follow-up [poster]. In: World Congress of Nephrology; 31 May-4 Jun 2013; Hong Kong.
24. Legendre C, Cohen D, Delmas Y, et al. Efficacy of eculizumab in atypical hemolytic uremic syndrome (aHUS) patients with or without prior transplant [abstract plus poster]. In: European Renal Association-European Dialysis & Transplant Association 50th Congress; 18-21 May 2013; Istanbul.
25. Hillmen P, Muus P, Roth A, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162(1):62-73.
26. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013;12(6):554-62.
27. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83(4):233-44. (Pubitemid 38955446)
28. Alexion Pharmaceuticals. aHUS observational long term follow-up (LTFU) [ClinicalTrials.gov identifier NCT01522170] US National Institutes of Health. Clinical Trials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01522170. Accessed 10 Feb 2014.
29. Alexion Pharmaceuticals. Atypical hemolytic-uremic syndrome (aHUS) registry [ClinicalTrials.gov identifier NCT01522183] US National Institutes of Health. Clinical Trials.gov. 2014. http://www.clinicaltrials.gov/ct2/show/ NCT01522183. Accessed 10 Feb 2014.